


**Remarks**

The main purpose of this paper is to address a rejection of the claims based on an alleged lack of unity (PCT Rule 13). Specifically, the Examiner had previously asserted that eight separate inventions existed in the claims. However, as a result of two telephone conferences including Examiner Chu and Mr. Seurer on 10 February 2006, an agreement was made whereby the subject matter of Groups I, II, and III would be examined in the present application.

Applicant would like to thank the Examiner for his time discussing the issue of unity of invention. To assist the Examiner in his search, Applicant has provided a species from which the search can be started. The elected species corresponds to the formula below:




wherein X is  $^{18}\text{F}$ ; m is 1; n is 1; and R is phenyl.

With regard to the claims amendments, independent Claim 1 has been amended to include the subject matter of original Claim 4, namely, that the halogen is radioactive. Claim 4 has thus been cancelled, as have Claims 7-8, which depended from cancelled Claim 4. To comply with the Examiner's restriction requirement, Claims 12-24 have been cancelled from this application. It should be noted that Claims 4, 7-8 and 12-24 have been cancelled without prejudice and with right of reentry of the subject matter of any of those claims in this or any other appropriate patent application.

It is believed that the present application is now in condition for allowance. Accordingly, a notice of allowance is respectfully requested. Should the Examiner feel that a telephone conference would expedite allowance, the Examiner is invited to contact the undersigned.

Respectfully submitted,

  
Jerad G. Seurer (Reg. No. 45,467)  
Mallinckrodt Inc.  
314-654-3814  
jerad.seurer@tycohealthcare.com